Slide 1: Investors Update – Q3FY11
Investors Update – Q3FY11 • Net sales up 23% at Rs 374 crores against Rs. 303 crores in corresponding quarter last year • Profit before tax up by 153% at Rs. 36.88 crores against Rs. 14.55 crores in corresponding quarter in PY • Net Profit up by 127% at Rs. 30.84 crores against Rs. 13.58 crores in c
Slide 2: Management Discussion – Q3FY11
Management Discussion – Q3FY11 Alembic Limited, the pharmaceutical major, today reported a 23% increase in revenues to Rs 373.79 crores for the quarter ended 31st December 2010, compared to Rs 303.30 crores in the corresponding quarter last year. The Company posted an impressive 127% growth in net p
Slide 3: ORG IMS Nov '10 MAT Growth and Top Brands
(ORG IMS – Nov ‘10 MAT Growth %) Segment Alembic Industry Cough and Cold 21 18 Cardio 20 19 Opthal 254 23 Alembic has five brands in the list of top 300 brands of the industry: Brands Rank Nov ‘10 Azithral 18 Althrocin 34 Roxid 69 Wikoryl 140 Zeet 284 Last quarter witnessed declining trend of Anti-i
Slide 4: International Generics and API Business
¾ International Generics ( Regulated Markets) International generics grew by 109% to Rs. 51.72 crores from Rs. 24.78 Crores over corresponding quarter last year Alembic’s strategy is to partner with International Generic companies and leverage on their marketing and sales capabilities. Filings with
Slide 5: Financial and Operating Result – Q3FY11
Interest Net Interest costs during the quarter was at Rs. 7.91 crores compared to Rs. 6.77 crores largely on account of successive rate increases. Financial and Operating Result – Q3FY11 Financial and Operating Result - Q3FY11 Particulars Q3FY11 Q3FY10 Gr % Income from Operations 36627 30090 22% Tot
Slide 6: Summary of Total Revenue and Profit Break-up
Summary of total revenue (consolidated) for the quarter is as under: (Rs. in Lacs) Particulars Q3FY11 Q3FY10 % Change Formulation Domestic 18424 15351 20% International Branded 1504 916 64% International Generics 5172 2478 109% API Domestic 6899 3474 98% International ROW 2784 1866 49% International
Slide 7: Scheme of Rearrangement
Scheme of Rearrangement: The Company is awaiting approval of its scheme of Arrangement from Hon’ble High Court of Gujarat. The Company has complied with all other requirements in this aspect. After the demerger becomes effective, application will be made to BSE and NSE to list Alembic Pharma Ltd The
Slide 8: Business Performance of Proposed Pharma Limited and Proposed Alembic Limited
Business Performance of Proposed Pharma Limited and Proposed Alembic Limited: Business Performance - Sales (Proposed Alembic Pharma Rs. Limited) Lacs Particulars Formulations Bulk Total Q3FY11 Q3FY10 Gr % Q3FY11 Q3FY10 Gr % Q3FY11 Q3FY10 Gr % Domestic 18424 15351 20% 3368 552 510% 21792 15903 37% Ex
Slide 9: Break up of Alembic Pharma Limited / Alembic Limited
Beak up of Alembic Pharma Limited / Alembic Limited Sales and Profit break up of both businesses depicted below are as per best estimate of management and have not been audited (Rs. in Lacs) Pharma Operations Baroda Operations (Proposed Alembic (Proposed Alembic Particulars Pharma Limited) Limited)
Slide 10: About Alembic Limited
About Alembic Limited Established in 1907, Alembic Ltd. is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macroli